• In the last year, Health Canada's Pest Management Regulatory Agency has been criticized
for not releasing information about the safety of pesticides because data are considered …

How do you change the way an institution has worked for nearly a century? This is the
challenge that the biomedical com mun ity must help Health Canada confront if the regu …

Health Canada considers confidential the information submitted by a manufacturer in
requesting approval for a drug and at present does not publicly disclose that a product is …

T he effective development of public health policy requires that decision-makers and their
scientific advisers have access to vital information. This statement appears to be a truism …

Pharmaceutical manufacturers have long considered results collected from drugs' clinical
trials to be confidential information or trade secrets, even after submission to the Food and …

Should doctors, patients, and policymakers have complete informa-tion about new drugs?
Complete transparency may seem like the obvious answer. But the reality is that available …

In Canada, the information used to approve new drugs is deemed commercially sensitive
and hence confidential under the Access to Information Act, 1 and the Therapeutic Products …

Regulatory agencies such as Health Canada and the US Food and Drug Administration
(FDA) have to date treated submissions of clinical trial data as confidential business …

On April 13, 2000, the Canadian Parliament enacted by Royal Assent the Personal
Information Protection and Electronic Documents Act (PIPEDA). 1 The Act requires private …

The British government must take the lead in ending the secrecy surrounding the
manufacture, licensing, and marketing of new drugs in Europe, says the National Consumer …